Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NVCR Stock Forecast 2026-2027
$17.16
Current Price
$1.99B
Market Cap
Buy 5
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to NVCR Price Targets
+179.7%
To High Target of $48.00
+57.3%
To Median Target of $27.00
-0.9%
To Low Target of $17.00
NVCR Price Momentum
+0.7%
1 Week Change
+4.0%
1 Month Change
+0.9%
1 Year Change
+32.7%
Year-to-Date Change
-10.9%
From 52W High of $19.25
+74.7%
From 52W Low of $9.82
📊 TOP ANALYST CALLS
Did NVCR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Novocure is one of their latest high-conviction picks.
Latest NVCR Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, NVCR has a bullish consensus with a median price target of $27.00 (ranging from $17.00 to $48.00). The overall analyst rating is Strong Buy (8.6/10). Currently trading at $17.16, the median forecast implies a 57.3% upside. This outlook is supported by 5 Buy, 2 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Larry Biegelsen at Wells Fargo, suggesting a 0.9% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NVCR Analyst Ratings
5
Buy
2
Hold
0
Sell
NVCR Price Target Range
Low
$17.00
Average
$27.00
High
$48.00
Current: $17.16
Latest NVCR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NVCR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 4, 2026 | Wells Fargo | Larry Biegelsen | Equal-Weight | Maintains | $17.00 |
| May 1, 2026 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $20.00 |
| Apr 16, 2026 | Wedbush | Neutral | Reiterates | $N/A | |
| Feb 26, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 12, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jan 15, 2026 | Wedbush | Neutral | Reiterates | $N/A | |
| Jan 13, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Oct 30, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Oct 27, 2025 | JP Morgan | Neutral | Maintains | $N/A | |
| Jul 25, 2025 | Wells Fargo | Equal-Weight | Downgrade | $N/A | |
| Jul 8, 2025 | Ladenburg Thalmann | Buy | Initiates | $N/A | |
| Jun 27, 2025 | Piper Sandler | Overweight | Reiterates | $N/A | |
| Apr 23, 2025 | Piper Sandler | Overweight | Maintains | $N/A | |
| Apr 16, 2025 | Wedbush | Neutral | Maintains | $N/A | |
| Apr 10, 2025 | JP Morgan | Neutral | Maintains | $N/A | |
| Jan 14, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 13, 2024 | Piper Sandler | Overweight | Maintains | $N/A | |
| Dec 3, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Dec 2, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 2, 2024 | Evercore ISI Group | Outperform | Upgrade | $N/A |
NovoCure Ltd. (NVCR) Competitors
The following stocks are similar to Novocure based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
NovoCure Ltd. (NVCR) Financial Data
NovoCure Ltd. has a market capitalization of $1.99B with a P/E ratio of -14.1x. The company generates $674.41M in trailing twelve-month revenue with a -25.7% profit margin.
Revenue growth is +12.3% quarter-over-quarter, while maintaining an operating margin of -38.7% and return on equity of -50.0%.
Valuation Metrics
Market Cap
$1.99B
Enterprise Value
$1.89B
P/E Ratio
-14.1x
PEG Ratio
-0.1x
Price/Sales
3.1x
Growth & Margins
Revenue Growth (YoY)
+12.3%
Gross Margin
+77.6%
Operating Margin
-38.7%
Net Margin
-25.7%
EPS Growth
+12.3%
Financial Health
Cash/Price Ratio
+21.7%
Current Ratio
2.9x
Debt/Equity
71.0x
ROE
-50.0%
ROA
-11.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
NovoCure Ltd. (NVCR) Business Model
About NovoCure Ltd.
What They Do
Develops non-invasive cancer therapy using electric fields.
Business Model
Novocure Ltd. generates revenue through the commercialization of its innovative Tumor Treating Fields (TTFields) therapy, which includes FDA-approved products for treating various aggressive cancers. The company's business model relies on manufacturing and distributing wearable devices that patients use to manage their cancer treatment, while ongoing clinical trials aim to expand their product offerings and indications.
Additional Information
With a focus on reducing the side effects associated with traditional chemotherapy, Novocure operates in multiple international markets and is continuously researching new applications for its technology. Established in 2000 and headquartered in Jersey, the company is well-positioned to impact the oncology landscape significantly.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
1,488
CEO
Ms. Ashley Cordova
Country
Switzerland
IPO Year
2015
Website
www.novocure.comNovoCure Ltd. (NVCR) Latest News & Analysis
Latest News
Quick Summary
NovoCure (NVCR) reported international revenue performance that influences Wall Street analysts' financial predictions and impacts future stock prospects.
Why It Matters
NovoCure's international revenue trends influence Wall Street forecasts, impacting investor sentiment and stock valuation, highlighting growth potential or risks in the company's market strategy.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
NovoCure Limited (NVCR) held its Q1 2026 earnings call, discussing their financial performance and strategic updates. Further details on revenue and forecasts were provided.
Why It Matters
The Q1 2026 earnings call for NovoCure Limited provides insights into the company's financial health, performance metrics, and future guidance, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Novocure (NASDAQ: NVCR) reported strong Q1 2026 financial results, highlighting progress in its commercial and clinical programs for Tumor Treating Fields therapy.
Why It Matters
Novocure's strong Q1 results and progress in its cancer treatment programs can boost investor confidence, potentially leading to increased stock value and interest in the oncology sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
NovoCure (NVCR) reported a quarterly loss of $0.62 per share, worse than the Zacks Consensus Estimate of a $0.40 loss, and compared to a loss of $0.31 per share a year prior.
Why It Matters
NovoCure's larger-than-expected quarterly loss raises concerns about financial health and operational efficiency, potentially impacting investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Novocure and Glaukos outperformed Wall Street's Q1 expectations, leading the Medical-Products industry group.
Why It Matters
Novocure and Glaukos beating Q1 expectations signals strong performance in the Medical-Products sector, potentially boosting investor confidence and stock prices in the industry.
Source: Investors Business Daily
Market Sentiment:
Neutral
Quick Summary
NovoCure Limited has resolved its CMS billing issue. Q1 2026 revenues rose 12% to $174.1M, with gross margins at 78%. Full-year guidance increased to $690–710M amid mixed product performance.
Why It Matters
NovoCure's resolution of the CMS billing issue and revenue growth signal operational stability, while raised guidance indicates confidence. However, mixed product performance introduces risk.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About NVCR Stock
What is NovoCure Ltd.'s (NVCR) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, NovoCure Ltd. (NVCR) has a median price target of $27.00. The highest price target is $48.00 and the lowest is $17.00.
Is NVCR stock a good investment in 2026?
According to current analyst ratings, NVCR has 5 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $17.16. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NVCR stock?
Wall Street analysts predict NVCR stock could reach $27.00 in the next 12 months. This represents a 57.3% increase from the current price of $17.16. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is NovoCure Ltd.'s business model?
Novocure Ltd. generates revenue through the commercialization of its innovative Tumor Treating Fields (TTFields) therapy, which includes FDA-approved products for treating various aggressive cancers. The company's business model relies on manufacturing and distributing wearable devices that patients use to manage their cancer treatment, while ongoing clinical trials aim to expand their product offerings and indications.
What is the highest forecasted price for NVCR NovoCure Ltd.?
The highest price target for NVCR is $48.00 from at , which represents a 179.7% increase from the current price of $17.16.
What is the lowest forecasted price for NVCR NovoCure Ltd.?
The lowest price target for NVCR is $17.00 from Larry Biegelsen at Wells Fargo, which represents a -0.9% decrease from the current price of $17.16.
What is the overall NVCR consensus from analysts for NovoCure Ltd.?
The overall analyst consensus for NVCR is bullish. Out of 3 Wall Street analysts, 5 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $27.00.
How accurate are NVCR stock price projections?
Stock price projections, including those for NovoCure Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 9:12 AM UTC